Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
(2015) In Annals of the Rheumatic Diseases 74(8). p.1530-1536- Abstract
- Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE. Methods Recently diagnosed (< 15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression. Results We studied 1150... (More)
- Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE. Methods Recently diagnosed (< 15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression. Results We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index > 1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort. Conclusions MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/7779734
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 74
- issue
- 8
- pages
- 1530 - 1536
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000357683600020
- scopus:84940393297
- pmid:24692585
- ISSN
- 1468-2060
- DOI
- 10.1136/annrheumdis-2013-203933
- language
- English
- LU publication?
- yes
- id
- 6784bb6f-7516-4b0a-a1bf-7eff4bad9cf0 (old id 7779734)
- date added to LUP
- 2016-04-01 12:51:42
- date last changed
- 2022-02-19 01:27:21
@article{6784bb6f-7516-4b0a-a1bf-7eff4bad9cf0,
abstract = {{Background The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE. Methods Recently diagnosed (< 15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression. Results We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index > 1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort. Conclusions MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.}},
author = {{Parker, Ben and Urowitz, Murray B. and Gladman, Dafna D. and Lunt, Mark and Donn, Rachelle and Bae, Sang-Cheol and Sanchez-Guerrero, Jorge and Romero-Diaz, Juanita and Gordon, Caroline and Wallace, Daniel J. and Clarke, Ann E. and Bernatsky, Sasha and Ginzler, Ellen M. and Isenberg, David A. and Rahman, Anisur and Merrill, Joan T. and Alarcon, Graciela S. and Fessler, Barri J. and Fortin, Paul R. and Hanly, John G. and Petri, Michelle and Steinsson, Kristjan and Dooley, Mary Anne and Manzi, Susan and Khamashta, Munther A. and Ramsey-Goldman, Rosalind and Zoma, Asad A. and Sturfelt, Gunnar and Nived, Ola and Aranow, Cynthia and Mackay, Meggan and Ramos-Casals, Manuel and van Vollenhoven, Ronald F. and Kalunian, Kenneth C. and Ruiz-Irastorza, Guillermo and Lim, S. Sam and Kamen, Diane L. and Peschken, Christine A. and Inanc, Murat and Bruce, Ian N.}},
issn = {{1468-2060}},
language = {{eng}},
number = {{8}},
pages = {{1530--1536}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort}},
url = {{https://lup.lub.lu.se/search/files/3018712/8626211}},
doi = {{10.1136/annrheumdis-2013-203933}},
volume = {{74}},
year = {{2015}},
}